Lipella pharmaceuticals announces u.s. patent allowance for innovative liposomal drug delivery platform

Patent application covers key technology innovations for delivering therapeutic agents proprietary technology enables precise delivery to improve safety and efficacy in oncology, cancer survivorship and immunotherapy allowance provides broad ip protection for drug-delivery platform and extends market exclusivity for two lead clinical assets currently in phase 2 trials pittsburgh, oct. 15, 2024 (globe newswire) -- lipella pharmaceuticals inc. (nasdaq: lipo), a clinical-stage biotechnology company focused on developing therapies for serious diseases with unmet medical needs, today announced the receipt of a notice of allowance from the u.s. patent and trademark office (uspto) for its proprietary liposomal drug delivery platform. the patent application, u.s. patent no.
LIPO Ratings Summary
LIPO Quant Ranking